2018

Here we are…barely finished with the first quarter of 2018, and the United States Food and Drug Administration (FDA) Office of…

Health Affairs and the National Pharmaceutical Council held a briefing focused on efforts to increase value and monitor costs on…

To control rising costs under Medicare, the Affordable Care Act, and Medicare Access and CHIP Reauthorization Act of 2015…

Earlier this year, CMS proposed changes to the Medicare Advantage and Part D programs through the Advanced Notice and Draft Call…

According to new releases from the FDA, it plans to look at several issues related to biopharma advertising and promotion. FDA is…

We have previously written about financial conflicts of interest and whether physicians can disseminate impartial scientific…

Drug pricing transparency, as a concept at least, is here to stay. However, the details of what that means and the new obligations…

On Thursday, March 15, 2018, the United States Senate Committee on Health, Education, Labor & Pensions held a hearing…

On Wednesday, April 4, 2018, Food and Drug Administration (FDA) Commissioner Scott Gottlieb spoke at the National Rx Drug Abuse…

Recently the Committee on Energy and Commerce Subcommittee on Health held a hearing entitled, “Combating the Opioid Crisis:…